SABR for operable stage I non-small-cell lung cancer: comparison to surgery

I read the Article by Joe Y Chang and colleagues 1 Chang JY Mehran RJ Feng L et al. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021; 22: 1448-1457 Summary Full Text Full Text PDF PubMed Scopus (48) Google Scholar published in The Lancet Oncology with great interest. Stereotactic ablative radiotherapy (SABR) was non-inferior to video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND) for operable stage IA non-small-cell lung cancer. Here, we present three discussion points regarding this trial. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgeryLong-term survival after SABR is non-inferior to VATS L-MLND for operable stage IA NSCLC. SABR remains promising for such cases but multidisciplinary management is strongly recommended. Full-Text PDF SABR for operable stage I non-small-cell lung cancer: comparison to surgeryWe read with great interest the Article published in The Lancet Oncology by Joe Y Chang and colleagues,1 which provided the current high-level evidence that for patients with operable stage IA non-small-cell lung cancer, stereotactic ablative radiotherapy (SABR) and radical surgery showed equivalent long-term overall survival. However, there are still great controversies regarding the quality control and efficacy evaluation of different treatment options for non-small-cell lung cancer, which should arouse the attention of doctors. Full-Text PDF SABR for operable stage I non-small-cell lung cancer: comparison to surgery – Authors' replyWe appreciate the instructive comments from Tairo Kashihara, Meng-Si Luo, and Jiaqi Zhang and colleagues on our revised STARS trial that was published in The Lancet Oncology.1 Full-Text PDF SABR for operable stage I non-small-cell lung cancer: comparison to surgeryIn The Lancet Oncology, Joe Y Chang and colleagues1 compared the effects of stereotactic ablative radiotherapy (SABR) and video-assisted thoracoscopic surgical lobectomy with mediastinal lymph node dissection (VATS L-MLND) for operable stage I non-small-cell lung cancer. Full-Text PDF